Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression-Reference-Cited by-同舟云学术

Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression

Published:2024-09-04 Issue: Volume: Page:
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Soufivand Parviz,Hosseini Torshizi Ghazal,Roghani Seyed Askar,Dastbaz Mohammad,Lotfi Ramin^ORCID,Soleymani Bijan,Heydarpour Fatemeh,Abdan Zahra,Allahyari Hosna

Funder

Deputy for Research and Technology, Kermanshah University of Medical Sciences

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10787-024-01565-1.pdf

Reference36 articles.

1. Adi SD, Eiza N, Bejar J et al (2019) Semaphorin 3A is effective in reducing both inflammation and angiogenesis in a mouse model of bronchial asthma. Front Immunol 10:550. https://doi.org/10.3389/fimmu.2019.00550

2. Alunno A, Manetti M, Caterbi S et al (2015) Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm 2015:751793. https://doi.org/10.1155/2015/751793

3. Alzabin S, Williams RO (2011) Effector T cells in rheumatoid arthritis: lessons from animal models. FEBS Lett 585:3649–3659. https://doi.org/10.1016/j.febslet.2011.04.034

4. Catalano A (2010) The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 185:6373–6383. https://doi.org/10.4049/jimmunol.0903527

5. Cozacov R, Halasz K, Haj T et al (2017) Semaphorin 3A: is a key player in the pathogenesis of asthma. Clin Immunol 184:70–72. https://doi.org/10.1016/j.clim.2017.05.011